This collaboration will see Indoco launch around 20 products in UK over the next 18 months through Clarity Pharma, which will serve as its distributor. Shares of Indoco Remedies Ltd ended at ₹ 321, down by ₹ 3.85, or 1.19%, on the BSE.

Drugmaker Indoco Remedies Ltd on Monday (December 2) announced that the company has entered a strategic partnership with Clarity Pharma of UK.

This collaboration will see Indoco launch approximately 20 products in the UK over the next 18 months through Clarity Pharma, which will serve as its distributor. The company will continue to supply all the products under the existing B2B partnership to its clients.

Aditi Panandikar, Managing Director, Indoco Remedies, said, "This collaboration with Clarity Pharma is a significant milestone for Indoco as this will further strengthen our foothold in the UK pharma market. By combining Indoco’s robust portfolio of high-quality, affordable pharmaceutical products with Clarity Pharma’s strong distribution network and market expertise, we are poised to deliver innovative healthcare solutions to a broader patient base."

Steve Soper, CEO of Clarity Pharma, said, "Today is the beginning of a truly exciting journey between Indoco and Clarity and is the result of several years’ hard work in putting this market access project together. The range of Indoco products is exciting and extensive and will deliver significant savings to the market once launched, we look forward to a bright future of collaboration, growth, and making a difference in the affordability of a wide range of medicines."

Shares of Indoco Remedies Ltd ended at ₹ 321, down by ₹ 3.85, or 1.19%, on the BSE. (Edited by : Shoma Bhattacharjee)